{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:00:23Z","timestamp":1791270023956,"version":"4.1.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n The treatment landscape for hepatocellular carcinoma (HCC) is rapidly evolving, with the approval of multiple systemic therapies for patients with advanced disease since 2017. However, ideal treatment sequencing approaches remain unknown, and data on clinical practice patterns are limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate current treatment patterns, sequencing, and survival outcomes among patients receiving systemic therapy for HCC.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study used data from a nationwide electronic health record (EHR)\u2013derived database of more than 280 oncology practices at more than 800 US cancer clinics to assess adult patients who were treated with systemic therapy for HCC from January 1, 2011, to December 31, 2023.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n First-line systemic therapy type.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Overall survival (OS) was defined as the time from first-line systemic therapy initiation to death, last clinical activity, or the censor date of December 31, 2023. Progression-free survival (PFS) was defined as the time from first-line systemic therapy initiation to the earliest of EHR-documented disease progression, death, last clinical encounter, or the censor date.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 4198 patients (median [IQR] age, 67 [61-74] years; 3353 [79.9%] male), sorafenib was the most common first-line systemic therapy until it was overtaken by atezolizumab-bevacizumab in 2020; durvalumab-tremelimumab also became a common first-line therapy in 2023. Of the full study cohort, 871 (20.7%) received second-line therapy. Median OS was 8.1 months (95% CI, 7.7-8.6 months) but was not significantly associated with first-line systemic therapy type. Median PFS was 3.9 months (95% CI, 3.7-4.0 months); first-line atezolizumab-bevacizumab (hazard ratio, 0.84; 95% CI, 0.71-0.99) was associated with improved PFS compared with sorafenib.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and relevance<\/jats:title>\n In this cohort study of patients treated with systemic therapy for HCC between 2011 and 2023, atezolizumab-bevacizumab and durvalumab-tremelimumab emerged as the most common first-line systemic therapies administered for HCC, but relatively few patients received second-line therapy. Additional research is needed to determine optimal treatment sequencing and increase the likelihood that patients may benefit from second-line systemic therapy options.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.51665","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T16:30:33Z","timestamp":1767112233000},"page":"e2551665","source":"Crossref","is-referenced-by-count":5,"title":["Treatment Patterns and Survival Outcomes Among Patients With Hepatocellular Carcinoma"],"prefix":"10.1001","volume":"8","author":[{"given":"Kelsey S.","family":"Lau-Min","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Massachusetts General Hospital, Boston"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela C.","family":"Tramontano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin","family":"Iheanacho","sequence":"additional","affiliation":[{"name":"Warren Alpert Medical School of Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Adam","family":"Abrams","sequence":"additional","affiliation":[{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Manz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"issue":"Suppl 1","key":"zoi251373r2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma.","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"zoi251373r3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-0030-1247128","article-title":"Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis.","volume":"30","author":"Sherman","year":"2010","journal-title":"Semin Liver Dis"},{"key":"zoi251373r4","first-page":"1","article-title":"Surgery and portal hypertension.","volume":"1","author":"Child","year":"1964","journal-title":"Major Probl Clin Surg"},{"issue":"8","key":"zoi251373r5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices.","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg"},{"issue":"6","key":"zoi251373r6","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi251373r7","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update.","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"4","key":"zoi251373r8","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma.","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi251373r9","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1200\/OP-24-00872","article-title":"Management of advanced hepatocellular carcinoma: a review and practical guide.","volume":"21","author":"Nagalapuram","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"20","key":"zoi251373r10","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi251373r11","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"issue":"1","key":"zoi251373r13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35649","article-title":"Changing treatment patterns for hepatocellular carcinoma: a Surveillance, Epidemiology, and End Results-Medicare study.","volume":"131","author":"Iheanacho","year":"2025","journal-title":"Cancer"},{"issue":"6","key":"zoi251373r16","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/1475-6773.13669","article-title":"Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States.","volume":"56","author":"Zhang","year":"2021","journal-title":"Health Serv Res"},{"key":"zoi251373r18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1180962","article-title":"Approach to machine learning for extraction of real-world data variables from electronic health records.","volume":"14","author":"Adamson","year":"2023","journal-title":"Front Pharmacol"},{"key":"zoi251373r19","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.23.00046","article-title":"Raising the bar for real-world data in oncology: approaches to quality across multiple dimensions.","volume":"8","author":"Castellanos","year":"2024","journal-title":"JCO Clin Cancer Inform"},{"issue":"4","key":"zoi251373r20","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"zoi251373r21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1023\/A:1011240019516","article-title":"Socioeconomic status and breast cancer incidence in California for different race\/ethnic groups.","volume":"12","author":"Yost","year":"2001","journal-title":"Cancer Causes Control"},{"issue":"5","key":"zoi251373r22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"9","key":"zoi251373r23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.35066","article-title":"Survival outcomes among patients with hepatocellular carcinoma in a large integrated US health system.","volume":"7","author":"Yilma","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"10308","key":"zoi251373r24","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","article-title":"Liver cirrhosis.","volume":"398","author":"Gin\u00e8s","year":"2021","journal-title":"Lancet"},{"key":"zoi251373r25","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae342","article-title":"Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience.","author":"Marell","year":"2025","journal-title":"Oncologist"},{"issue":"Suppl 2","key":"zoi251373r26","doi-asserted-by":"publisher","first-page":"ii58","DOI":"10.1136\/qhc.12.suppl_2.ii58","article-title":"Administrative data based patient safety research: a critical review.","volume":"12","author":"Zhan","year":"2003","journal-title":"Qual Saf Health Care"},{"issue":"13","key":"zoi251373r27","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2012.404","article-title":"Finding pure and simple truths with administrative data.","volume":"307","author":"Sarrazin","year":"2012","journal-title":"JAMA"},{"key":"zoi251373r1","unstructured":"International Agency for Research on Cancer, World Health Organization. The Global Cancer Observatory. Liver Fact Sheet. Updated December 2020. Accessed May 4, 2023. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/11-liver-and-intrahepatic-bile-ducts-fact-sheet.pdf"},{"key":"zoi251373r12","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Hepatocellular Carcinoma. Accessed November 11, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hcc.pdf"},{"key":"zoi251373r14","unstructured":"Flatiron Health. Database Characterization Guide. Accessed April 9, 2025. https:\/\/flatiron.com\/database-characterization"},{"key":"zoi251373r15","doi-asserted-by":"crossref","unstructured":"Ma? X, Long? L, Moon? S, Adamson? BJS, Baxi? SS. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR.? medRxiv. 2020:2020.03.16.20037143. doi:10.1101\/2020.03.16.20037143","DOI":"10.1101\/2020.03.16.20037143"},{"key":"zoi251373r17","unstructured":"Birnbaum? BNN, Seidl-Rathkopf? K, . Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. arXiv. Preprint posted January 13, 2020. doi:10.48550\/arXiv.2001\/09765"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2843236\/laumin_2025_oi_251373_1766090491.7288.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T16:30:34Z","timestamp":1767112234000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2843236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.51665","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]}}}